D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of chemotherapy combined
with dendritic activated cytokine-induced killer cell (D-CIK) for non-small cell lung cancer
(NSCLC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shenzhen Hornetcorn Bio-technology Company, LTD
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University Affiliated Tumor Hospital of Guangzhou Medical University